Hidradenitis suppurativa (HS) is a clinically heterogeneous disease with few effective treatments.1 While clinical examination forms the basis for HS diagnosis and evaluation, HS clinical heterogeneity poses substantial challenges for assessing disease severity, activity, and treatment response.2 Efforts to accurately quantify HS severity and treatment response have resulted in the development of more than 30 investigator- and patient-reported outcome measures, several of which are unvalidated and some of which are unresponsive to changes in disease, that have been used in more than 12 randomized clinical trials, thus limiting comparisons of evidence across trials.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Naik HB. Importance of Standardized Nomenclature to Advance Hidradenitis Suppurativa Research and Clinical Care. JAMA Dermatol. Published online March 10, 2021. doi:10.1001/jamadermatol.2020.5466
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: